ADMA Biologics, Inc. (ADMA) NASDAQ
7.98
+0.05(+0.63%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
7.98
+0.05(+0.63%)
Currency In USD
| Previous Close | 7.93 |
| Open | 8 |
| Day High | 8.18 |
| Day Low | 7.97 |
| 52-Week High | 22.37 |
| 52-Week Low | 7.21 |
| Volume | 1.89M |
| Average Volume | 7.11M |
| Market Cap | 1.85B |
| PE | 11.74 |
| EPS | 0.68 |
| Moving Average 50 Days | 9.81 |
| Moving Average 200 Days | 14.96 |
| Change | 0.05 |
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutica
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated Year-End 2025 Cash Grew to Approximately $88 M